- Novo Holdings has completed its $16.5 billion acquisition of Catalent, Inc., taking the company private.
- Catalent’s three fill-finish sites will be acquired by Novo Nordisk shortly after the transaction.
Catalent, Inc., a leader in drug development and manufacturing solutions, is now part of Novo Holdings following a completed acquisition valued at approximately $16.5 billion. The all-cash transaction grants holders of Catalent common stock $63.50 per share, representing a 47.5% premium to the stock’s 60-day volume-weighted average price as of February 2, 2024.
Alessandro Maselli, Catalent’s President and CEO, emphasised the milestone, stating, “With Novo Holdings’ partnership and support, we are well-positioned to deliver unparalleled outcomes for our customers and the patients they serve.”
Kasim Kutay, CEO of Novo Holdings, highlighted the alignment between Catalent’s mission and Novo Holdings’ purpose to invest for people and the planet.
Catalent’s stock has been delisted from the New York Stock Exchange. In a related move, Novo Nordisk will acquire Catalent’s fill-finish sites in Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium, further leveraging its biopharmaceutical capabilities.
